Intermediate results of the prospective randomized controlled trial VOG-01: "Evaluation of the efficacy of neoadjuvant combination hormone therapy in premenopausal patients with ER+ HER2- breast cancer". (2022). Voprosy Onkologii, 68(3), 354-361. https://doi.org/10.37469/0507-3758-2022-68-3-354-361